Before You Give Up on ImClone

The scandal-rocked drugmaker looks like it'll never shake its woes, but tantalizing hints of progress on its cancer drug Erbitux are appearing

By Catherine Arnst

To continue reading this article you must be a Bloomberg Professional Service Subscriber.